Vacinas para a Hanseníase
DOI:
https://doi.org/10.47878/hi.2003.v28.35294Resumo
.
Downloads
Não há dados estatísticos.
Referências
1 BRENNAN M.J.; FRUTH U. Global forum on TB vaccine research and development. World Health Organization, June 7-8 2001, Geneva. Tuberculosis, Edinb, v.81, p.365-368, 2001.
2 COLE, S.T. and 43 others. Massive gene decay in the leprosy bacillus. Nature, v. 409, n. 6823, p.1007-1011, 2001.
3 CONVIT, J. Studies of leprosy in the German ethnic group of Colonia Tovar, Venezuela. V. The morbidity rates in BCG vaccinated and unvaccinated Groups during five years. Int. J. Leprosy., v.24, p.269-274, 1956.
4 CONVIT. J. An investigation of leprosy in the German ethnic group of Colonia Tovar in Venezuela. IV. Clinical findings and variations
in the Mantoux and Mitsuda reactions observed during five years after vaccination of Mitsuda-negative contacts. Int. J. Leprosy., v.24, p.38-44, 1956.
5 CONVIT, J.; ULRICH, M. Immunotherapy and immunoprophylaxis of leprosy. Indian J. Leprosy., v.72, p.21-32, 2000.
6 CONVIT, J.; ARANZAZU, N.; PINARDI, M.E.; ULRICH, M. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation on a mixture of Mycobacterium leprae and BCG. Clin. Exp. Immunol., v. 36, 214-220, 1979.
7 CONVIT, J.; ARANZAZU, N.; ULRICH, M.; PINARDI, M.E.; REYES, O.; ALVARADO, J. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts. Int. J. Leprosy., v.50, 415-424,1982.
8 CONVIT, J.; SAMPSON, C.; ZÚÑIGA, M.; SMITH, P.G.; PLATA, J.; SILVA, J.; MOLINA, J.; PINARDI, M.E.; BLOOM, B.R.; SALGADO, A. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet, v.339, n. 8791, 446-450, 1992.
9 CONVIT, J.; SMITH, P.G.; ZÚÑIGA, M.; SAMPSON, C.; ULRICH, M.; PLATA, J.; SILVA, J.; MOLINA, J.; SALGADO, A. BCG vaccination protects against leprosy in Venezuela: A case-control study. Int. J. Leprosy., v. 61, p. 185-191, 1993.
10 DOHERTY, T.M.; ANDERSON, P. Tuberculosis vaccine development. Curr. Opin. Pulm. Med., v.8, p.183-187, 2002.
11 FINE, P.E.; SMITH P.G. Vaccination against leprosy - the view from 1996. Leprosy Rev., v. 67, p. 249-252, 1996.
12 GUPTE, M.D. and 13 others Comparative leprosy vaccine trial in south India. Indian J. Leprosy., v. 70, p. 369-388, 1998.
13 WORLD HEALTH ORGANIZATION. Immunology of Mycobacterial Diseases (IMMYC) Steering Committee, Analysis of vaccines prepared from armadillo-derived Mycobacterium leprae. Results of an inter-laboratory study coordinated by the World Health Organization. Int. J. Leprosy, v. 63, p.,48-55, 1995.
14 JAMET, P.; JI, B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int. J. Leprosy., v. 63, p. 195-201, 1995.
15 KARONGA PREVENTION TRIAL GROUP Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae/BCG vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet, v. 348, n. 9019, p. 17-24, 1996.
16 KIRCHHEIMER, W.F.; STORRS, E.E. Attempts to establish the armadillo (Dasypus novemcinctus Linn) as a model for the study
of leprosy. I. Report of lepromatoid leprosy in an infected armadillo. Int. J. Leprosy. v. 39, p. 693-702, 1971.
17 LECHAT, M.F.; MISSON, C.B.; BOUCKAERT, A.; VELLUT, C. An epidemiometric model of leprosy a computer simulation of various control methods with increasing coverage. Int. J. Leprosy., v. 45, p. 1-8, 1977.
18 MEYERS, W.; WALSH, G.P.; BROWN, H.L.; REES, R.J.W.; CONVIT, J. Naturally acquired leprosy-like disease in the ninebanded armadillo (Dasypus novemcinctus): Reactions in leprosy patients to lepromins prepared from naturally infected armadillos. J. Reticuloendoth. Soc., v. 22, p. 369-375, 1977.
19 PONNIGHAUS, J.M.; FINE, P.E.; STERNE, J.A.; WILSON, R.J.; MSOSA, E.; GRUER, P.J.; JENKINS, P.A.; LUCAS, S.B; LIOMBA, N.G.; BLISS, L. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet, v. 339, n. 8794, p. 636-639, 1992.
20 TOKUNAGA, T.; YAMAMOTO, T.; YAMAMOTO S. How BCG led to the discovery of immunostimulatory DNA. Japan J. Inf. Dis., v. 52, p. 1-11, 1992.
21 WHO Report of a special meeting of the leprosy elimination advisory group (LEAG) with potential partners. WHO/LEP, n. 99.1, p. 1-19, 1999.
22 YOUNG, S.; O’DONNELL, M.; LOCKHART, E.; BUDDLE, B.; SLOBBE, L.; LUO, Y.; DE LISLE, G. ; BUCHAN, G. Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18- secreting recombinant bacillus Calmette Guerin. Immunol. Cell. Biol., v. 80, p., 209-215, 2002.
2 COLE, S.T. and 43 others. Massive gene decay in the leprosy bacillus. Nature, v. 409, n. 6823, p.1007-1011, 2001.
3 CONVIT, J. Studies of leprosy in the German ethnic group of Colonia Tovar, Venezuela. V. The morbidity rates in BCG vaccinated and unvaccinated Groups during five years. Int. J. Leprosy., v.24, p.269-274, 1956.
4 CONVIT. J. An investigation of leprosy in the German ethnic group of Colonia Tovar in Venezuela. IV. Clinical findings and variations
in the Mantoux and Mitsuda reactions observed during five years after vaccination of Mitsuda-negative contacts. Int. J. Leprosy., v.24, p.38-44, 1956.
5 CONVIT, J.; ULRICH, M. Immunotherapy and immunoprophylaxis of leprosy. Indian J. Leprosy., v.72, p.21-32, 2000.
6 CONVIT, J.; ARANZAZU, N.; PINARDI, M.E.; ULRICH, M. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation on a mixture of Mycobacterium leprae and BCG. Clin. Exp. Immunol., v. 36, 214-220, 1979.
7 CONVIT, J.; ARANZAZU, N.; ULRICH, M.; PINARDI, M.E.; REYES, O.; ALVARADO, J. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts. Int. J. Leprosy., v.50, 415-424,1982.
8 CONVIT, J.; SAMPSON, C.; ZÚÑIGA, M.; SMITH, P.G.; PLATA, J.; SILVA, J.; MOLINA, J.; PINARDI, M.E.; BLOOM, B.R.; SALGADO, A. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet, v.339, n. 8791, 446-450, 1992.
9 CONVIT, J.; SMITH, P.G.; ZÚÑIGA, M.; SAMPSON, C.; ULRICH, M.; PLATA, J.; SILVA, J.; MOLINA, J.; SALGADO, A. BCG vaccination protects against leprosy in Venezuela: A case-control study. Int. J. Leprosy., v. 61, p. 185-191, 1993.
10 DOHERTY, T.M.; ANDERSON, P. Tuberculosis vaccine development. Curr. Opin. Pulm. Med., v.8, p.183-187, 2002.
11 FINE, P.E.; SMITH P.G. Vaccination against leprosy - the view from 1996. Leprosy Rev., v. 67, p. 249-252, 1996.
12 GUPTE, M.D. and 13 others Comparative leprosy vaccine trial in south India. Indian J. Leprosy., v. 70, p. 369-388, 1998.
13 WORLD HEALTH ORGANIZATION. Immunology of Mycobacterial Diseases (IMMYC) Steering Committee, Analysis of vaccines prepared from armadillo-derived Mycobacterium leprae. Results of an inter-laboratory study coordinated by the World Health Organization. Int. J. Leprosy, v. 63, p.,48-55, 1995.
14 JAMET, P.; JI, B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int. J. Leprosy., v. 63, p. 195-201, 1995.
15 KARONGA PREVENTION TRIAL GROUP Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae/BCG vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet, v. 348, n. 9019, p. 17-24, 1996.
16 KIRCHHEIMER, W.F.; STORRS, E.E. Attempts to establish the armadillo (Dasypus novemcinctus Linn) as a model for the study
of leprosy. I. Report of lepromatoid leprosy in an infected armadillo. Int. J. Leprosy. v. 39, p. 693-702, 1971.
17 LECHAT, M.F.; MISSON, C.B.; BOUCKAERT, A.; VELLUT, C. An epidemiometric model of leprosy a computer simulation of various control methods with increasing coverage. Int. J. Leprosy., v. 45, p. 1-8, 1977.
18 MEYERS, W.; WALSH, G.P.; BROWN, H.L.; REES, R.J.W.; CONVIT, J. Naturally acquired leprosy-like disease in the ninebanded armadillo (Dasypus novemcinctus): Reactions in leprosy patients to lepromins prepared from naturally infected armadillos. J. Reticuloendoth. Soc., v. 22, p. 369-375, 1977.
19 PONNIGHAUS, J.M.; FINE, P.E.; STERNE, J.A.; WILSON, R.J.; MSOSA, E.; GRUER, P.J.; JENKINS, P.A.; LUCAS, S.B; LIOMBA, N.G.; BLISS, L. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet, v. 339, n. 8794, p. 636-639, 1992.
20 TOKUNAGA, T.; YAMAMOTO, T.; YAMAMOTO S. How BCG led to the discovery of immunostimulatory DNA. Japan J. Inf. Dis., v. 52, p. 1-11, 1992.
21 WHO Report of a special meeting of the leprosy elimination advisory group (LEAG) with potential partners. WHO/LEP, n. 99.1, p. 1-19, 1999.
22 YOUNG, S.; O’DONNELL, M.; LOCKHART, E.; BUDDLE, B.; SLOBBE, L.; LUO, Y.; DE LISLE, G. ; BUCHAN, G. Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18- secreting recombinant bacillus Calmette Guerin. Immunol. Cell. Biol., v. 80, p., 209-215, 2002.
Downloads
Publicado
30-06-2003
Como Citar
1.
Convit J, Borges R, Ulrich M, Aranzazu N, Pinardi ME, Parra JJ. Vacinas para a Hanseníase. Hansen. Int. [Internet]. 30º de junho de 2003 [citado 30º de abril de 2024];28(1):7-12. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35294
Edição
Seção
Artigos originais
Licença
Este periódico está licenciado sob uma Creative Commons Attribution 4.0 International License.
